Cleveland BioLabs, Inc. (CBLI) relating to its proposed merger with Cytocom, Inc. Under the terms of the agreement, BioLabs shareholders will retain only 39% control of the combined company.
Cleveland BioLabs, Inc. (CBLI) relating to its proposed merger with Cytocom, Inc. Under the terms of the agreement, BioLabs shareholders will retain only 39% control of the combined company.